Cysteamine therapy: A treatment for cystinosis, not a cure

Kidney International

Volumn 81, Issue 2, 2012, Pages 127-129

  Cherqui, Stephanie ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTAMINE;

CTNS GENE; CYSTINOSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE; GENE DELETION; HALITOSIS; HOMOZYGOSITY; HUMAN; KIDNEY FAILURE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84855184663     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.301     Document Type: Note

References (14)

1. Kalatzis V , Cherqui S , Antignac C, et al. Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. E MBO J 2001; 20: 5940-5949. (Pubitemid 33049269)
2. Gahl WA , Thoene J , Schneider JA. Cystinosis: a disorder of lysosomal membrane transport. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease , 8th edn. McGraw Hill: New York, 2001; 3 : pp 5085-5108.
3. Thoene JG , Oshima RG , Crawhall JC, et al. Cystinosis. Intracellular cystine depletion by aminothiols i n vitro and in vivo. J Clin Invest 1976; 58 : 180-189.
4. Gahl WA , Balog JZ , Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med 2007 ; 147 : 242-250. (Pubitemid 351664580)
5. Nesterova G , Gahl W. Nephropathic cystinosis: late complications of a multisystemic disease. Pediatr Nephrol 2008; 23: 863-878.
6. Brodin-Sartorius A , Tte M - J , Niaudet P, et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int 2012; 81: 1 79-1 89.
7. North American Pediatric Renal Trials and Collaborative Studies 2010 and 2011. Annual Reports. http://www.emmes.com/study/ped/annlrept/annlrept.html (2010-2011, accessed June) 2011.
8. Cure Cystinosis International Registry. https://cystinosis. patientcrossroads.org (accessed June 2011).
9. Gahl WA , Reed GF , Thoene JG, et al. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 1987; 3 16: 971-977. (Pubitemid 17055375)
10. Gahl WA , Charnas L , Markello TC, et al. Parenchymal organ cystine depletion with long-term cysteamine therapy. B iochem Med Metab Biol 1992 ; 4 8 : 275-285. (Pubitemid 23049971)
11. Nevo N , Chol M , Bailleux A, et al. Renal phenotype of the cystinosis mouse model is dependent upon genetic background. N ephrol Dial Transplant 2010; 25 : 1059-1066.
12. Dohil R, Gangoiti JA, Cabrera BL, et al. Long-term treatment of cystinosis in children with twice-daily cysteamine. J Pediatr 2010; 156: 8 23-8 27.
13. Syres K , Harrison F , Tadlock M, et al. Successful treat ment of the murine model of cystinosis using bone marrow cell transplantation. B lood 2009; 1 14: 2542-2552.
14. Yeagy BA , Harrison F , Gubler MC, et al. Kidney preservation by bone marrow cell transplantation in hereditary nephropathy. Kidney Int 2011; 7 9: 1198-1206.